When was CinFina Pharma founded?

CinFina Pharma was founded in 2021.

Where is CinFina Pharma located?

CinFina Pharma is headquartered in Cincinnati, United States.

Who is the current CEO of CinFina Pharma?

Jonathan Isaacsohn of CinFina Pharma. They have also founded 1 company.

Is CinFina Pharma a funded company?

CinFina Pharma is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does CinFina Pharma rank among its competitors?

CinFina Pharma ranks 114th amongst 145 active competitors, of which 50 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Congruence Therapeutics, which secured $39.5M in Mar, 2026.

Who are the top competitors of CinFina Pharma?

CinFina Pharma's top competitors include MannKind Corp, Corcept and Adocia. Among them, Congruence Therapeutics secured the most recent funding round in March, 2026.

CinFina Pharma - 2026 Company Profile, Team & Competitors

CinFina Pharma is an unfunded company based in Cincinnati (United States), founded in 2021 by Jonathan Isaacsohn. It operates as a Developer of therapeutics for metabolic diseases. CinFina Pharma has not raised any funding yet. The company has 145 active competitors, including 50 funded and 44 that have exited. Its top competitors include companies like MannKind Corp, Corcept and Adocia.

Company Details

Developer of therapeutics for metabolic diseases. It offers monotherapy and combination treatments which include CIN-109, CIN-110, CIN-209, and CIN-210 for obesity and assosiated co-morbidities.

Website: cinfina.com
Email ID: *****@cinrx.com
Part Of

Key Metrics

Founded Year

2021

Location

Cincinnati, United States

Stage

Unfunded

Ranked

114^th among 145 active competitors

Similar Companies

Adocia & 86 more

View CinFina Pharma's full profile

CinFina Pharma has not raised any funding rounds yet.

The founders of CinFina Pharma is Jonathan Isaacsohn. Jonathan Isaacsohn is the CEO of CinFina Pharma.

Here are the details of CinFina Pharma's key team members:

Jonathan Isaacsohn: Founder & CEO of CinFina Pharma.
Contact Info: 1 email address

View details of CinFina Pharma's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CinFina Pharma include MannKind Corp, Corcept and Adocia. Here is the list of Top 10 competitors of CinFina Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	73/100
2nd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, Longitude Capital & 6 others	69/100
3rd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
4th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Orbimed, Longitude Capital & 3 others	67/100
5th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Third Rock Ventures, Pfizer Venture Investments ... & 8 others	67/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Sanofi, Orbimed & 5 others	65/100
7th	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Kinnevik, Lux Capital & 29 others	63/100
8th	Aardark Therapeutics 2017, San Diego (United States), Public	Provider of small molecules therapeutics for treating obesity and rare genetic metabolic disorders	$138M	Decheng Capital, Sorrento Therapeutics & 16 others	63/100
9th	Congruence Therapeutics 2021, Montreal (Canada), Series B	Developer of therapeutics for the treatment of rare diseases	$136M	Amplitude, Orbimed & 9 others	62/100
10th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Evotec & 1 others	62/100
114th	CinFina Pharma 2021, Cincinnati (United States), Unfunded	Developer of therapeutics for metabolic diseases	-	-	26/100